iBio, Inc. (IBIO)
NYSEAMERICAN: IBIO · IEX Real-Time Price · USD
1.760
+0.040 (2.33%)
Apr 26, 2024, 4:00 PM EDT - Market closed
iBio, Inc. Revenue
iBio, Inc. had revenue of $50.00K in the twelve months ending December 31, 2023, down -97.22% year-over-year.
Revenue (ttm)
$50.00K
Revenue Growth
-97.22%
P/S Ratio
299.74
Revenue / Employee
$1,923
Employees
26
Market Cap
14.99M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2023 | 0 | - | - |
| Jun 30, 2022 | 1.88M | -487.00K | -20.54% |
| Jun 30, 2021 | 2.37M | 733.00K | 44.75% |
| Jun 30, 2020 | 1.64M | -380.00K | -18.83% |
| Jun 30, 2019 | 2.02M | 1.57M | 354.50% |
| Jun 30, 2018 | 444.00K | 50.00K | 12.69% |
| Jun 30, 2017 | 394.00K | -554.00K | -58.44% |
| Jun 30, 2016 | 948.00K | -903.00K | -48.78% |
| Jun 30, 2015 | 1.85M | 1.65M | 802.93% |
| Jun 30, 2014 | 205.00K | -802.00K | -79.64% |
| Jun 30, 2013 | 1.01M | -270.00K | -21.14% |
| Jun 30, 2012 | 1.28M | 756.92K | 145.54% |
| Jun 30, 2011 | 520.08K | - | - |
| Jun 30, 2010 | 0 | - | - |
| Jun 30, 2009 | 1.18M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Flora Growth | 76.07M |
| ETAO International Co. | 58.06M |
| Psychemedics | 22.10M |
| Immuron | 2.43M |
| ABVC BioPharma | 152.43K |
| BioSig Technologies | 18.00K |
| Cardio Diagnostics Holdings | 17.07K |
IBIO News
- 4 weeks ago - iBio stock nearly tripled on Wednesday: here's why - Invezz
- 4 weeks ago - iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases - GlobeNewsWire
- 4 weeks ago - iBio Announces $15.0 Million Private Placement - GlobeNewsWire
- 2 months ago - iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka - GlobeNewsWire
- 3 months ago - iBio Announces Participation in 23rd Annual PepTalk Conference - GlobeNewsWire
- 3 months ago - Top 4 Health Care Stocks That May Rocket Higher In Q1 - AlloVir (NASDAQ:ALVR), GRI Bio (NASDAQ:GRI) - Benzinga
- 4 months ago - iBio Amends and Extends Maturity of Credit Agreement - GlobeNewsWire
- 5 months ago - iBio, Inc. Announces Pricing of $4.5 Million Public Offering - GlobeNewsWire